

**ABSTRACT OF THE DISCLOSURE**

Methods for promoting an HIV-1 specific immune response in adult and  
5 pediatric patients having HIV-1 infections as well as patients co-infected with HIV-  
1 and HCV involving administering a therapeutically effective amount of pegylated  
interferon-alfa, e.g. , pegylated interferon alfa-2b are disclosed.